Logo image
Engineering a Nanoscale Al-MOF-Armored Antigen Carried by a “Trojan Horse”-Like Platform for Oral Vaccination to Induce Potent and Long-Lasting Immunity
期刊文章

Engineering a Nanoscale Al-MOF-Armored Antigen Carried by a “Trojan Horse”-Like Platform for Oral Vaccination to Induce Potent and Long-Lasting Immunity

Y.-B. Miao, W.-Y. Pan, K.-H. Chen, H.-J. Wei, F.-L. Mi, M.-Y. Lu, Y. Chang 和 H.-W. Sung
Advanced Functional Materials, 卷.29(43)
2019
Web of Science ID: WOS:000482646200001

摘要

aluminum adjuvant biomimetic mineralization drug delivery metal–organic framework yeast capsule Antigens Armor Armored vehicles Biomimetics Controlled drug delivery Drug delivery Mineralogy Molecular biology Proteolysis Targeted drug delivery Vaccines Yeast Biomimetic mineralization Delivery vehicle Gastrointestinal Mucosal barriers Nanoscale Al Oral administration Oral vaccinations Transepithelial transport Military vehicles
Vaccination via the oral administration of an antigen faces many challenges, including gastrointestinal (GI) proteolysis and mucosal barriers. To limit GI proteolysis, a biomimetically mineralized aluminum-based metal–organic framework (Al-MOF) system that is resistant to ambient temperature and pH and can act synergistically as a delivery vehicle and an adjuvant is synthesized over a model antigen ovalbumin (OVA) to act as armor. To overcome mucosal barriers, a yeast-derived capsule is used to carry the Al-MOF-armored OVA as a “Trojan Horse”-like transport platform. In vitro experiments reveal that the mineralization of Al-MOFs forms an armor on OVA that protects against highly acidic and degradative GI conditions. However, the mineralized Al-MOFs can gradually disintegrate in a phosphate ion-containing simulated intracellular fluid, slowly releasing their encapsulated OVA. In vivo studies reveal that the “Trojan Horse”-like transport platform specifically targets intestinal M cells, favoring the transepithelial transport of the Al-MOF-armored OVA, followed by subsequent endocytosis in local macrophages, ultimately accumulating in mesenteric lymph nodes, yielding long-lasting, high-levels of mucosal S-IgA and serum IgG antibodies. Such an engineered delivery platform may represent a promising strategy for the oral administration of prophylactic or therapeutic antigens for vaccination. © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

檔案與連結 (1)

url
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071076183&doi=10.1002%2fadfm.201904828&partnerID=40&md5=c5ca7ccedd1043b6930fbbcad29ce815檢視

相關連結

指標

1 檢視次數

詳細資料

Logo image